LONDON – Cambridge Nutritional Sciences plc (AIM: CNSL), a specialist in medical diagnostics, has been served with a court summons for its subsidiary, Omega Diagnostics, over alleged breaches of Health, Safety and Environment (HSE) regulations dating back to 2018. The infractions pertain to the management of biological agents at a facility operated by Omega South West, a former entity of Omega Diagnostics Limited, which was sold along with the implicated facility in the same year.
The company has acknowledged the summons and disclosed a first hearing is set for March 18, 2025. Cambridge Nutritional Sciences is currently in consultation with legal advisers to determine the most suitable response for its stakeholders and has committed to providing updates as the situation evolves.
The alleged violations are historical and occurred prior to the divestment of Omega South West, which has since ceased trading and is no longer part of Cambridge Nutritional Sciences’ operations or business model. The company has also clarified that no current employees were involved with Omega South West at the time of the alleged offences.
Cambridge Nutritional Sciences, listed on the AIM market of the London Stock Exchange (LON:), is known for its emphasis on personalized health and nutrition through its diagnostic products. As the case involves historical allegations, the company has not indicated any immediate impact on its current business activities.
This legal development comes as the company is navigating an increasingly complex regulatory landscape, with industry observers closely watching the outcome of such proceedings. The press release statement from Cambridge Nutritional Sciences serves as the source of this report, providing the public and investors with transparent updates regarding the legal challenge faced by the company’s subsidiary.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
